BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31675246)

  • 1. Immortal Time Bias Question in the Association Between Toxicity and Outcome of Immune Checkpoint Inhibitors.
    Dall'Olio FG; Di Nunno V; Massari F
    J Clin Oncol; 2020 Jan; 38(1):105-106. PubMed ID: 31675246
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.
    Braschi-Amirfarzan M; Tirumani SH; Hodi FS; Nishino M
    Korean J Radiol; 2017; 18(1):42-53. PubMed ID: 28096717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers associated with checkpoint inhibitors.
    Manson G; Norwood J; Marabelle A; Kohrt H; Houot R
    Ann Oncol; 2016 Jul; 27(7):1199-206. PubMed ID: 27122549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
    Spain L; Larkin J
    Immunotherapy; 2016 Jun; 8(6):677-9. PubMed ID: 27197536
    [No Abstract]   [Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitor Therapy in Patients With Autoimmune Disease.
    Johnson DB; Beckermann KE; Wang DY
    Oncology (Williston Park); 2018 Apr; 32(4):190-4. PubMed ID: 29684232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress of immune checkpoint therapy in the clinic (Review).
    Fan Y; Zhang C; Jin S; Gao Z; Cao J; Wang A; Li D; Wang Q; Sun X; Bai D
    Oncol Rep; 2019 Jan; 41(1):3-14. PubMed ID: 30365127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitors in lung cancer: an update.
    Sullivan K; Preeshagul I; Budman D; Seetharamu N
    Future Oncol; 2017 May; 13(11):955-959. PubMed ID: 28481150
    [No Abstract]   [Full Text] [Related]  

  • 9. Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?
    Masterson L; Howard J; Gonzalez-Cruz J; Jackson C; Barnett C; Overton L; Liu H; Ladwa R; Simpson F; McGrath M; Wallwork B; Jones T; Ottensmeier C; Chua MLK; Perry C; Khanna R; Panizza B; Porceddu S; Lechner M
    Int J Cancer; 2020 Apr; 146(8):2305-2314. PubMed ID: 31950498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cochleovestibular toxicity induced by immune checkpoint inhibition: a case series.
    Lemasson J; Cuzzubbo S; Doucet L; Gounant V; Baroudjian B; Herms F; Carpentier AF; Lebbé C; Vitaux H; Hautefort C; Delyon J;
    Eur J Cancer; 2019 Aug; 117():116-118. PubMed ID: 31279302
    [No Abstract]   [Full Text] [Related]  

  • 11. Biomarker challenges for immune checkpoint inhibitors in urothelial carcinoma.
    Powles T; Morrison L
    Nat Rev Urol; 2018 Oct; 15(10):585-587. PubMed ID: 30030491
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of TLR4 and B7-H1 on immune escape of urothelial bladder cancer and its clinical significance.
    Wang YH; Cao YW; Yang XC; Niu HT; Sun LJ; Wang XS; Liu J
    Asian Pac J Cancer Prev; 2014; 15(3):1321-6. PubMed ID: 24606459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitors: a new era for esophageal cancer.
    Zou LQ; Yang X; Li YD; Zhu ZF
    Expert Rev Anticancer Ther; 2019 Aug; 19(8):731-738. PubMed ID: 31424306
    [No Abstract]   [Full Text] [Related]  

  • 14. Do immune-related adverse events correlate with response to immune checkpoint inhibitors?
    Saleh K; Khalife-Saleh N; Kourie HR
    Immunotherapy; 2019 Mar; 11(4):257-259. PubMed ID: 30678551
    [No Abstract]   [Full Text] [Related]  

  • 15. Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways.
    Sasikumar PG; Ramachandra M
    BioDrugs; 2018 Oct; 32(5):481-497. PubMed ID: 30168070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibition in ovarian cancer.
    Hamanishi J; Mandai M; Konishi I
    Int Immunol; 2016 Jul; 28(7):339-48. PubMed ID: 27055470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.
    Chen YM
    J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view.
    Memon H; Patel BM
    Life Sci; 2019 Sep; 233():116713. PubMed ID: 31386875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Herzberg B; Campo MJ; Gainor JF
    Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heather Wakelee on the Role of Checkpoint Inhibitors in Advanced Lung Cancer.
    Wakelee H
    Oncology (Williston Park); 2017 Jun; 31(6):440, 442. PubMed ID: 28620899
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.